The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
ImmunoSarc II master trial (phase II of sunitinib and nivolumab): Results from the dedifferentiated chondrosarcoma (DDCS) cohort—A GEIS, ISG and UCL study.
 
Sandra J. Strauss
Consulting or Advisory Role - Boehringer Ingelheim; Ceridwen Oncology; GlaxoSmithKline; InhibRx
Speakers' Bureau - Boehringer Ingelheim
Travel, Accommodations, Expenses - Adaptimmune
 
Nadia Hindi
Honoraria - PharmaMar; Tecnofarma
Consulting or Advisory Role - GlaxoSmithKline; PharmaMar
Research Funding - Adaptimmune (Inst); Ayala Pharmaceuticals (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb/Pfizer (Inst); CEBIOTEX (Inst); Deciphera (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Immix BioPharma (Inst); InhibRx (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Lixte Biotechnology (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Philogen (Inst); PTC Therapeutics (Inst); Rain Therapeutics (Inst)
Travel, Accommodations, Expenses - PharmaMar
 
Emanuela Palmerini
Consulting or Advisory Role - Deciphera pharmaceuticals, llc cf; SynOX
 
Javier Martínez-Trufero
Consulting or Advisory Role - Boehringer Ingelheim Spain; Deciphera; Eisai; GlaxoSmithKline; PharmaMar
Research Funding - Ayala Pharmaceuticals (Inst); BionTech (Inst); Blueprint Medicines (Inst); Daiichi Sankyo (Inst); Kariopharm Therapeutics (Inst); Lilly (Inst); PharmaMar (Inst); Syneos Health (Inst); SynOX (Inst)
Travel, Accommodations, Expenses - Merck; PharmaMar; PharmaMar; Roche
 
Antonio Lopez-Pousa
No Relationships to Disclose
 
Irene Carrasco-Garcia
Honoraria - PharmaMar
Speakers' Bureau - PharmaMar
Research Funding - Cogent Medicine (Inst); PharmaMar (Inst)
Travel, Accommodations, Expenses - PharmaMar
 
Enrique Gonzalez-Billalabeitia
Consulting or Advisory Role - AstraZeneca; Bayer; Janssen Oncology
Research Funding - AstraZeneca; Merck
Travel, Accommodations, Expenses - Astellas Pharma; Bristol-Myers Squibb; Bristol-Myers Squibb; Janssen-Cilag; Pfizer; Pfizer; Roche; Sanofi
 
David Silva Moura
Honoraria - Tecnofarma
Research Funding - Eisai (Inst); Immix BioPharma (Inst); Novartis (Inst); PharmaMar (Inst)
Travel, Accommodations, Expenses - Bayer; Eisai; Pfizer; PharmaMar
 
Rafael Ramos
No Relationships to Disclose
 
Roberto Tirabosco
No Relationships to Disclose
 
Antonio Gutierrez
No Relationships to Disclose
 
Javier Martin Broto
Leadership - Sarcoma Research Solutions SL
Consulting or Advisory Role - Amgen; Asofarma; Bayer; Boehringer Ingelheim; GlaxoSmithKline; Lilly; Novartis; PharmaMar; Roche; Tecnofarma
Speakers' Bureau - PharmaMar
Research Funding - Adaptimmune; Amgen (Inst); Arog (Inst); Ayala Pharmaceuticals (Inst); Bayer (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); CEBIOTEX (Inst); Celgene (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Eisai; Eisai (Inst); FORMA Therapeutics (Inst); GlaxoSmithKline (Inst); Immix BioPharma (Inst); InhibRx (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Lixte Biotechnology (Inst); Nektar (Inst); Novartis; Novartis (Inst); Pfizer (Inst); PharmaMar; PharmaMar (Inst); Philogen (Inst); PTC Therapeutics (Inst); Rain Therapeutics (Inst); SpringWorks Therapeutics (Inst)
Expert Testimony - Novartis; PharmaMar
Travel, Accommodations, Expenses - Pfizer; PharmaMar